Healthcare Stocks

Sareum (SAR) returns 700% in a year: Is this small-cap share still a good buy?

 Sareum (SAR) returns 700% in a year: Is this small-cap share still a good buy?

HIGHLIGHTS Saerum raised £2.37 million in June 2021 through two subscription contracts with high-net-worth individuals. In July 2021, the company received approval from the US Patent and Trademark Office for the use of SDC-1802 drug molec...

Read More...
How These 2 Healthcare Stocks Performed Amid Pandemic Challenge

How These 2 Healthcare Stocks Performed Amid Pandemic Challenge

Source: BlurryMe, Shutterstock Summary: UK's leading cell and gene therapy firm Oxford Biomedica reported a 37 per cent increase in its revenue to £87.7 million for FY20. PureTech’s operating losses shrunk from $135.39 million in 201...

Read More...
Crypto Kings: Extraordinary Tale of Coinbase Founders Brian Armstrong, Fred Ehrsam

Crypto Kings: Extraordinary Tale of Coinbase Founders Brian Armstrong, Fred Ehrsam

Source: DSkorynko, Shutterstock Summary Although Coinbase made a smashing debuted on NASDAQ, opening 4% higher than the reference price, the Company had humble beginnings. Co-founders Fred Ehrsam and Brian Armstrong met on Reddit and built the...

Read More...
Covid-19 Vaccine Makers in News: J&J, AstraZeneca and Pfizer

Covid-19 Vaccine Makers in News: J&J, AstraZeneca and Pfizer

Source: insta_photos, Shutterstock Summary J&J delays the distribution of its Covid-19 vaccine to Europe. US may not use the AstraZeneca vaccine, says the chief pandemic adviser to the White House. Pfizer is likely to meet its US supply t...

Read More...
AstraZeneca’s Farxiga Fails to Yield Statistical Significance for Covid-19 Treatment

AstraZeneca’s Farxiga Fails to Yield Statistical Significance for Covid-19 Treatment

and concerns of using SGLT2 inhibitors to treat Covid-19 patients admitted to hospital. Things are not at all smooth for the pharma major AstraZeneca Plc (LON: AZN). After getting mired in various controversies related to its Covid-19 vaccine (...

Read More...
EMA Supports Astrazeneca Jabs Despite Links with Rare Blood Clots

EMA Supports Astrazeneca Jabs Despite Links with Rare Blood Clots

Source: LookerStudio, Shutterstock Summary The European Medicines Agency has said that the benefits of using AstraZeneca vaccine outweigh the potential risks it had highlighted before.  The MHRA is also scheduled to come up with an up...

Read More...
10 Cheap Healthcare Stocks to Ponder Over This Easter

10 Cheap Healthcare Stocks to Ponder Over This Easter

Source: Guschenkova, Shutterstock Summary On a YTD scale, healthcare stocks have multiplied the investors’ wealth by almost 2.5 times. Healthcare sector has a lot of ground to cover, and businesses can access a huge door of growth opport...

Read More...
Moderna vaccine to be rolled out in April as UK aims to vaccinate all adults by July

Moderna vaccine to be rolled out in April as UK aims to vaccinate all adults by July

Source: insta_photos, Shutterstock Summary The UK authorities said that first jabs of Moderna vaccine would be rolled out in April. The Boris Johnson government had said that it was committed to its plans to vaccinate the entire adult populati...

Read More...
Astrazeneca Vaccine Less Effective Than Earlier Touted, Claims Latest Trial Results

Astrazeneca Vaccine Less Effective Than Earlier Touted, Claims Latest Trial Results

Source: PhotobyTawat, Shutterstock Summary The Oxford-AstraZeneca vaccine is 76 per cent effective against the coronavirus infection. The earlier US clinical trial results had put the value a tad higher at 79 per cent. Despite the lower rate,...

Read More...
AstraZeneca Shares Making ‘Inverse Head And Shoulders’ Pattern Amid Vaccine Chaos

AstraZeneca Shares Making ‘Inverse Head And Shoulders’ Pattern Amid Vaccine Chaos

Source: PhotobyTawat, Shutterstock Summary Shares of AstraZeneca have experienced a turbulent trading session of late. The stock was trading at GBX 7,133, up 0.07 per cent on 19 March. This year so far, the stock has largely fallen extending ...

Read More...
Vaccine Stocks in Focus as AstraZeneca Awaits EU Verdict on Its Jabs

Vaccine Stocks in Focus as AstraZeneca Awaits EU Verdict on Its Jabs

Source: Aedka Studio, Shutterstock Summary AstraZeneca has recently faced suspensions from several countries and now is awaiting the EU medical watchdog’s official verdict. The company’s shares are still in the green as the World H...

Read More...